Corpus Intelligence IC Memo — HOSPITAL DAMAS 2026-04-26 05:22 UTC
IC Memo — HOSPITAL DAMAS
Investment Committee Memorandum | PR | 128 beds | Grade C | EBITDA uplift $4.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HOSPITAL DAMAS

CCN 400022 | nan, PR | 128 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HOSPITAL DAMAS is a 128-bed safety-net/medicaid heavy in nan, PR with $59.6M in net patient revenue and a -21.0% operating margin. The hospital serves a payer mix of 7.2% Medicare, 24.8% Medicaid, and 68.1% commercial.

Thesis: Undervalued. Our ML models identify $4.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -21.0% to -13.7% (+736bps).

Net Revenue HCRIS$59.6M
Current EBITDA COMPUTED$-12.5M
Operating Margin COMPUTED-21.0%
Occupancy HCRIS62.9%
Revenue / Bed COMPUTED$466K
Net-to-Gross HCRIS57.2%
Distress Probability ML53.6%

2. Market Context & Competitive Position

61
PR Hospitals
-8.8%
State Median Margin
38
Comparable Hospitals

PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of -21.0% places it below the state median. Among 38 size-comparable peers (64-256 beds), the median margin is -8.2%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (64-256), prioritizing same-state peers. 38 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HOSPITAL DAMAS (Target)PR128$59.6M-21.0%
HOSPITAL MENONITA DE CAYEYPR225$186.2M15.0%
ADMIN DE SERVICIOS MEDICOS DE PR65$179.7M-50.0%
HOSPITAL MENONITA CAGUAS INCPR232$114.1M6.8%
MAYAGUEZ MEDICAL CENTERPR210$102.8M7.6%
HOSPITAL PAVIA SANTURCEPR156$101.9M-9.4%
UNIVERSITY DISCTRICT HOSPITALPR210$97.4M-43.2%
HOSPITAL MENONITA AIBONITOPR129$92.1M-3.1%
HOSPITAL DE LA CONCEPCIONPR167$91.0M-3.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.3M+210bp18mo
Cost to Collect4.5%2.5%$1.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$726K+122bp9mo
Clean Claim Rate88.0%96.0%$38K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.3M
Cost to Collect
$1.2M
Denial Rate Reduction
$1.2M
A/R Days Reduction
$726K
Clean Claim Rate
$38K
Total EBITDA Uplift$4.4M
Current EBITDA$-12.5M
+ RCM Uplift+$4.4M
Pro Forma EBITDA$-8.2M
Current Margin-21.0%
Pro Forma Margin-13.7%
WC Released (1x)$2.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-19.3M$-38.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-19.3M$-49.0M0.00x-100.0%
Bull Case9.0x11.0x$-17.4M$-40.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-17.4M$-49.7M0.00x-100.0%
Bear Case11.0x10.0x$-21.2M$-54.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-21.2M$-66.9M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (24.8%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 53.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 38 hospitals with 64-256 beds
  • Same-state prioritization (n=39)
  • Comp margins: P25=-20.2% / P50=-8.2% / P75=1.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.